Navigation Links
IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS
Date:6/12/2009

ients with this chronic condition."

The 103 AS patients from 6 European countries (Belgium, Finland, France, Germany, the Netherlands and the United Kingdom) recruited to the 96-week open-label EASIC (European

Ankylosing Spondylitis Infliximab Cohort) trial had previously participated in the 2-year randomised controlled trial ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy). The EASIC population consisted of 82.5% men and 17.5% women, with a mean age of 43.5 years. There was no major difference between the EASIC and ASSERT study populations in terms of demographics or age.

Between the two trials, patients had a break from their clinical trial-prescribed treatment regime of 1.30.9 years, during which they were treated according to local clinical practice. According to differences in such local standards, one group of patients continued to receive IFX (group 2, n=89, 83 of whom went forward for analysis) and one group did not (group 1, n=14 all analysed). Of the latter, group 1a had relapsed (BASDAI >4 and physician global VAS >4) (n=9) and group 1b were in remission (n=5). Interestingly, all these relapsed patients (group 1a), who had not been treated with IFX during the period between the trials, flared at the time of start of EASIC.

During EASIC, all patients (except for those who had remained in remission) were continuously treated with IFX 5mg/kg (mean dosage) at intervals of 6-8 weeks (at the discretion of the investigator, according to local clinical practice). The patients in group 2 (who had also continuously received IFX between the trials) and completed the trial (n=76) showed significant improvement at week 96 compared to the ASSERT trial baseline data in a number of assessments:

  • BASDAI (Bath AS Disease Activity Index): 6.4 at ASSERT baseline vs 2.5 at week 96 of EASIC (p<0.001)
  • BASFI (Bath AS Functional Index): 5.9 vs 3.1 (p<0.001)
  • BASMI (Bath AS Metrology Index): 4.
    '/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. 30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
3. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
4. Study shows promise for new cancer-stopping therapy
5. MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3&#8482; Healthy Hormones&#8482;
6. Hormone therapy may confer more aggressive properties to prostate tumors
7. Pharmacy Organizations Brief Congress on Medication Therapy Management
8. Vaporized viral vector shows promise in anti-cancer gene therapy
9. Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
10. Cant Sleep? Try Online Therapy
11. Astellas Adds CNS Therapy Area Leader to Global R&D Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... FCCI Insurance Group has been again recognized ... Association for helping employees eat better and move more. ... in 2013, 2011, and 2010, and as a Gold-Level ... and wellness an important priority. We’re committed to providing ... top of their game, and we are honored to ...
(Date:7/23/2014)... Princeview Dental ( http://www.PrinceviewDental.com ), one ... of having a complete oral exam. , “Oral exams ... oral health care, as there are so many benefits ... founder of Princeview Dental. “Dentists are trained to detect ... Just by observing the inside of the mouth, we ...
(Date:7/23/2014)... Washington, DC (PRWEB) July 23, 2014 ... prompting some state-run insurance exchanges to come up ... identify some of the myriad ways to accomplish ... Information Services’s Inside Health Insurance Exchanges (HEX). , ... that high” for state-run exchanges, Christopher Condeluci, an ...
(Date:7/23/2014)... 2014 QueenBeeTickets.com is reducing the prices of ... for rock music fans who are still in the process ... the site, they can use promo code “DISCOUNT” to get ... to view the inventory of discounted tickets at QueenBeeTickets.com. , ... September and October, with The Eagles concert tickets literally disappearing ...
(Date:7/23/2014)... 23, 2014 Temecula Valley Southern ... Valley Southern California Wine Country artisan food and ... two nights genuinely nourishing. Savor like locals at ... and Vindemia wineries; EAT Marketplace, Palumbo’s Ristorante, Robin’s ... Olive Oil,” announced Kimberly Adams, president and CEO, ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3Health News:Princeview Dental, One of Etobicoke’s Trusted Dental Clinics, Addresses the Need to Have Complete Oral Exams 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:History of The Eagles Tour Tickets: QueenBeeTickets.com Reduces Prices on Remaining Inventory of Concert Tickets for 2014 Shows 2Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 2Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 3Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 4
... Subsidiary Continues its Strong Sales Presence in the ... Inc. ("Global Med" or the "Company") (OTC Bulletin ... company, today announced that its Inlog subsidiary has ... Software (Marketed as "Labo Serveur" in France) to ...
... cancers may be preventable, adopting a healthy lifestyle is more important than ... lifestyles than during busier times of the year. Texas Oncology suggests four ... out. , ... Dallas, Texas (PRWEB) May 27, 2009 -- With the ...
... Precyse Solutions, a leading provider of clinical documentation ... a two-year consulting and training agreement with IASIS ... includes peer-to-peer training regarding quality clinical documentation for ... its ability to utilize physician trainers to conduct ...
... N.J., May 27 Nuvilex, Inc. (OTC Bulletin ... today announces Jayhur Enterprises will distribute Infinitink (the ... removal) in Australia and New Zealand. The distribution ... exclusive contract to market, promote, market, distribute and ...
... side effect that could hamper immigration checks , , WEDNESDAY, ... drug capecitabine can cause people to lose their fingerprints, ... enter the United States, an oncologist warns. , Dr. ... the National Cancer Centre in Singapore, said he now ...
... Electronic Medical Record/Practice Management Software Company Aimed at ... TechnologyBLOOMFIELD HILLS, Mich., May 27 gloStream, a ... Microsoft Office embedded electronic medical record ("EMR") and ... has closed on a $7.5 million series B ...
Cached Medicine News:Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 2Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 3Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 2Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 3Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 5Health News:IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement 2Health News:IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement 3Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Fingerprints May Vanish With Cancer Drug 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 3Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 4
(Date:7/22/2014)... WASHINGTON , July 22, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... Mussallem today served as an expert panelist at ... Committee,s Subcommittee on Health to discuss medical device innovation ... Barriers to Ongoing Evidence Development and Communication." ...
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... -- The number of people overdosing from opioid prescription ... percent of the workforce has misused prescription painkillers, according ... making opioid use a serious threat to employee safety. ... correct dosage with a valid prescription, subtle impairment may ... Safety Council released a guide for employers, ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
... Merlin is a superior full-color, auto-focus, ... vision user in mind, Merlin enables the ... black and white, high contrast positive or ... video magnifier, this optional feature enables the ...
... purpose incubators designed to provide ... uniformity required for the most ... microprocessor controlled incubators feature push-button ... digital display, and built-in over-temperature ...
... Precision Economy Incubators available in five different ... of 1.4 cu. Ft. (39 liters), 2.5 ... ft. (129 liters. Equally important, Precision Economy ... excellent temperature sensitivity, stability, and uniformity. As ...
Aspheric diagnostic lens. 90D...
Medicine Products: